We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Impax Laboratories, Inc. (delisted) | NASDAQ:IPXL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.30 | 18.30 | 18.55 | 0 | 01:00:00 |
From May 2019 to May 2024
HAYWARD, Calif., Jan. 16, 2018 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on March 1, 2018.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at http://investors.impaxlabs.com.
To access the call through a conference line, dial (877) 356-3814 (in the U.S.) and (706) 758-0033 (international callers). The conference ID is 7677287.
A replay of the conference call will be available for seven days shortly after the call. To access the replay, dial (855) 859-2056 (in the U.S.) and (404) 537-3406 (international callers). The access code for the replay is 7677287.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
For more information, visit Impax's website at: www.impaxlabs.com.
Contact:
Mark Donohue
Investor Relations and Corporate Communications
(215) 558-4526
www.impaxlabs.com
View original content with multimedia:http://www.prnewswire.com/news-releases/impax-to-report-fourth-quarter-and-full-year-2017-results-on-march-1-2018-300582839.html
SOURCE Impax Laboratories, Inc.
Copyright 2018 PR Newswire
1 Year Impax Laboratories, Inc. (delisted) Chart |
1 Month Impax Laboratories, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
